Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.WT | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Financial Advisor

<< Previous

Bullboard Posts

Next >>

Comment by StevenBirchon Sep 26, 2023 12:03pm

183 Views

Post# 35654703

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Financial Advisor

You are right Dawg.

It's like Trading Places when Dan Ackroyd wants to pawn his watch and goes on and on about why it is worth thousands and Bo Diddley tells him "in Philadelphia it's worth 50 bucks".

We are in Philadelphia right now and no one will pay more than '50 bucks' until it is FDA approved. The cheerleaders understand this and the naysayers whether they understand that or not just want to stir it up.

But as you, Eog, Enrique, Wildbird etc. point out consistently the data is fantastic, on it's own and especially vis a vis the competition where you can draw valuation comparisons. Because of all that we can rightfully expect BTD in the near future. Roger puts his money where his mouth is and other insiders to a lesser extent but there is zero insider selling.

So we suffer these fools while we wait.

DJDawg wrote: Fair points.

For the safety signal, the safety data seems generally good for the number treated and given that it is a bladder instillation drug (rather than systemic) the true safety is likely to be reasonable compared to something intravenous.

Did you refer the most recent Swimmers plot? I find that a good visual.

One thing that led many of us here was the phase 1 b data. Are you familiar with that? It gives you a feel for the "potential" of the drug.

By way of recap, they treated 3 patients with full dose and full light intensity.

The 2 patients that were CRin the phase 1b had the following profiles.
patient 1
- 12 prior HCG treatment, 2 different tumour locations on the bladder wall.
patient 2
- 18 prior treatments, 3 different tumour locations on the bladder wall.

So the drug had to reach 5 different tumours and ablate them completely. It did so and those patients have stayed NMIBC free to 18 months. That was from one treatment at day 0.

While there are many cheerleaders and naysayers, most of us believe that a treatment that can do that in the phase 1b patients after only one treatment is probably worth more than 49 million CAD market cap.